Total-Body PET Patents: Top Companies & Filing Trends 2026
Total-Body and Long Axial PET Patents: Who Leads and Where Filing Has Cooled
54.8% concentration. The top five assignees account for 383 of the 699 records in scope — filing here is not evenly spread, it clusters hard at the top. Annual filings ran from 54 records in 2017 to a peak of 58 in 2022, then declined; the clearest complete-year comparison is 2021's 57 records against 2024's 21, a -63% move. Treat 2025 and 2026 as undercounted rather than as evidence the field has stopped.
- 1IMMUNOMEDICS INC172
- 2LANTHEUS MEDICAL IMAGING INC64
- 3CORNELL UNIVERSITY64
- 4SLOAN KETTERING INST FOR CANCER RES44
- 5IBC PHARMACEUTICALS INC39
See the full total-body and long axial pet analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions about total-body and long axial PET patents
Who holds the most patents in total-body and long axial PET?
One assignee leads the ranked field with 172 of the 699 records in scope, well ahead of fifth place at 39 and tenth place at 20. The top five assignees combined hold 383 records, or 54.8% of all records in scope, so the field is concentrated rather than evenly spread. A clearance or licensing review should treat that leader’s portfolio as the first stop, not one option among many.
Is patent filing in total-body PET slowing down?
Filing fell from 57 records in 2021 to 21 in 2024, a decline of 63% between the two most recent years that can be read as complete. Figures for 2025 and 2026 are still lower, but publication typically lags actual filing by around 18 months, so those most recent years understate true activity and should not be read as continued decline. The honest read is that filing peaked in 2022 at 58 records and has genuinely pulled back since, not that it has stopped.
What technology areas dominate the patent claims in this space?
Medicinal preparations (A61K) appear in 55.8% of the 699 records in scope, and peptide or protein claims (C07K) in 23.9%, reflecting how much of this filing activity is tracer and biomarker chemistry rather than scanner hardware. Diagnosis and surgery claims (A61B) sit at 21.6%, radiation measurement (G01T) at 11.6%, and image data processing (G06T) at only 9.3%. Because a single record can carry several classes, these shares add up to more than 100% and should be read against the 699-record total, not against each other as a closed set.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Total-Body and Long Axial PET covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.